Protara Therapeutics, Inc. Amortization of Debt Discount (Premium)
Protara Therapeutics, Inc. (TARA) reported Amortization of Debt Discount (Premium) of -$331.00 thousand for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-03.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2023-11-03
- Protara Therapeutics, Inc. amortization of debt discount (premium) for the quarter ending 2023-09-30 was -$127.00K, a 146.52% decline year-over-year.
- Protara Therapeutics, Inc. amortization of debt discount (premium) for the quarter ending 2022-09-30 was $273.00K.
- Protara Therapeutics, Inc. amortization of debt discount (premium) for the quarter ending 2021-03-31 was $283.00K.
- Protara Therapeutics, Inc. amortization of debt discount (premium) for the quarter ending 2014-12-31 was $0.00, a 100.00% decline year-over-year.
- Protara Therapeutics, Inc. amortization of debt discount (premium) for fiscal 2014 was $742.00K, a 0.93% decline from fiscal 2013.
- Protara Therapeutics, Inc. amortization of debt discount (premium) for fiscal 2013 was $749.00K.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|
| 2023-09-30 | -$127.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$331.00K 10-Q · filed 2023-11-03 | ||
| 2023-06-30 | -$204.00K 10-Q · filed 2023-08-03 | |||
| 2022-09-30 | $273.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $1.03M 10-Q · filed 2023-11-03 | ||
| 2022-06-30 | $756.00K 10-Q · filed 2023-08-03 | |||
| 2021-03-31 | $283.00K 10-Q · filed 2021-05-06 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $0.00 derived: sum of 2 quarters · filed 2017-03-16 | $1.00K derived: sum of 3 quarters · filed 2017-03-16 | $742.00K 10-K · filed 2017-03-16 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $1.00K derived: sum of 2 quarters · filed 2015-11-12 | $742.00K 10-Q · filed 2015-11-12 | $1.34M derived: sum of 4 quarters · filed 2016-03-14 |
| 2014-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | $742.00K 10-Q · filed 2015-08-13 | $1.34M derived: sum of 3 quarters · filed 2016-03-14 | |
| 2014-03-31 | $741.00K 10-Q · filed 2015-05-13 | $1.34M derived: sum of 2 quarters · filed 2016-03-14 | ||
| 2013-12-31 | $603.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | $749.00K 10-K · filed 2016-03-14 | ||
| 2013-09-30 | $146.00K 10-Q · filed 2014-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |